Wall Street brokerages predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will announce earnings of ($0.52) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.45). Kala Pharmaceuticals reported earnings per share of ($0.46) during the same quarter last year, which would suggest a negative year over year growth rate of 13%. The company is expected to announce its next earnings report on Monday, March 25th.
On average, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($2.11). For the next financial year, analysts forecast that the firm will post earnings of ($2.35) per share, with EPS estimates ranging from ($2.84) to ($2.03). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Thursday, November 8th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01).
In other Kala Pharmaceuticals news, Director Gregory Grunberg purchased 606,060 shares of the firm’s stock in a transaction on Friday, October 5th. The stock was bought at an average price of $8.25 per share, with a total value of $4,999,995.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Healthcare Fund Lp purchased 2,424,242 shares of the firm’s stock in a transaction on Wednesday, October 3rd. The stock was acquired at an average cost of $8.25 per share, with a total value of $19,999,996.50. The disclosure for this purchase can be found here. Company insiders own 35.58% of the company’s stock.
A number of hedge funds have recently modified their holdings of KALA. Alps Advisors Inc. purchased a new stake in shares of Kala Pharmaceuticals during the 2nd quarter worth $489,000. Wedbush Securities Inc. lifted its position in Kala Pharmaceuticals by 81.6% in the second quarter. Wedbush Securities Inc. now owns 56,420 shares of the company’s stock valued at $775,000 after acquiring an additional 25,350 shares during the last quarter. Rhumbline Advisers purchased a new stake in Kala Pharmaceuticals in the second quarter valued at $148,000. Bank of New York Mellon Corp lifted its position in Kala Pharmaceuticals by 23.2% in the second quarter. Bank of New York Mellon Corp now owns 41,327 shares of the company’s stock valued at $568,000 after acquiring an additional 7,784 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new stake in Kala Pharmaceuticals in the second quarter valued at $152,000. 49.61% of the stock is owned by institutional investors.
Kala Pharmaceuticals stock traded up $0.04 during trading on Monday, hitting $6.22. The company had a trading volume of 119,800 shares, compared to its average volume of 281,038. Kala Pharmaceuticals has a 1-year low of $6.01 and a 1-year high of $21.37. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.27 and a current ratio of 6.34. The company has a market capitalization of $208.86 million, a PE ratio of -1.07 and a beta of 0.63.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Recommended Story: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.